

**REMARKS**

Claims 1-23 are pending in the application. Claims 1-16 have been withdrawn from further consideration as being drawn to a non-elected invention. Claims 17-22 have been examined on the merits. The amendments to claims 17 and 22 have been made to include full names for various abbreviations. Support for the amendments can be found at *inter alia*, pages 21 and 63 in the specification. Support for the amendment to claim 17 regarding “chelates metal” can be found at page 34 in the specification, wherein the language “metal chelate functionality” is recited. Accordingly, no new matter has been introduced.

**Claim Objections**

Claim 17-22 have been objected to for reciting various abbreviations. The presently amended claims recite the full names. Therefore, this objection has been overcome.

**Rejection Under 35 U.S.C. 112, Second paragraph**

Claims 17-22 have been rejected as being indefinite. Applicant traverses this rejection. Reconsideration and withdrawal thereof are respectfully requested.

Claim 20 was rejected for reciting language that lacks antecedent basis. Claim 20 now depends from claim 18, which does provide antecedent basis. Therefore, this rejection has been overcome.

Claim 17 has been rejected because “metal chelator group” is not supported by the specification. Claim 17 has been amended to recite “chelates metal”, for which ample support is found in the specification, including page 34 in the specification.

**Rejection Under 35 U.S.C. 102**

Claims 17-22 have been rejected under 35 U.S.C. 102(b) as being anticipated over US Application No. 2003/0130293.

Regarding this publication, Applicant is considering converting the present application into a CIP application claiming priority to this currently pending application.

**Rejection Under 35 U.S.C. 112, First paragraph**


Claims 17-22 have been rejected as being not enabled by the specification. Applicant traverses this rejection. Reconsideration and withdrawal thereof are respectfully requested. However, the Examiner has indicated that the claims are enabled for breast, lung, colon, and prostate cancers. The claims have been amended to reflect the Examiner's comments. Accordingly, this rejection has been overcome.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

**JHK Law**

Dated: May 26, 2009

By:   
Joseph Hyosuk Kim, Ph.D.  
Reg. No. 41,425

P.O. Box 1078  
La Canada, CA 91012-1078  
(818) 249-8177 – direct  
(818) 249-8277 - fax